Move to topTop
January 26, 2017
20170126.jpg

Leuven, Belgium - Jan. 26, 2017 - In an exciting new era in drug development, the uptake of biopharmaceuticals drives more attention for the development of advanced drug delivery devices. Terumo and Nemera have taken benefit of their polymer science know-how to collaborate and provide the pharma industry with a unique combination of PLAJEX™ polymer-based PFS with Safe'n'Sound®.

PLAJEX™ is a sterile ready-to-fill COP syringe developed by Terumo with a strong focus towards biotherapeutic applications. Key features of PLAJEX™ include:

  • a silicone oil-free prefilled syringe system, integrating Terumo's proprietary i-coatingTM plunger stopper;
  • steam sterilized for mitigating protein oxidation and aggregation;
  • selected materials to minimize interactions with the drug product;
  • high transparency and resistance to breakage;
  • narrow dimensional tolerance of the moulded parts.

Safe'n'Sound® is a customizable platform of add-on passive sharps injury protection devices for PFS developed by Nemera. Amidst the key benefits, Safe'n'Sound® offers biopharmaceuticals with:

  • a passive device requiring no extra gesture from the user compared to a naked syringe;
  • strong resistance to shocks and vibrations for a robust and reliable functionality;
  • good visibility of the tip for easy inspection of the formulation even with low filling volume;
  • ergonomic features for ease of use.

To establish and confirm compatibility between PLAJEX™ and Safe'n'Sound®, Terumo and Nemera defined a development plan. The performance of this combination has been verified technically through a Design Verification Plan and validated by users through simulated clinical user studies. Preparations are ready for commercial supply: pharmaceutical clients are discussing several projects and plan to launch their drug product into the international market with the PLAJEX™ and Safe'n'Sound® injection system.

For further information, please refer to the whitepaper published in ONdrugDelivery - Prefilled syringe focus, edition N° 73, February 2017.

Find Terumo on the web at www.terumo.com

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over US$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Find Nemera on the web at www.nemera.net

Nemera is one of the world leaders in the design, development and manufacturing of drug delivery solutions. Its expertise covers all five modes of delivery: Parenteral (Safety devices, Autoinjectors and Pens), Nasal/Buccal/Auricular (spray pumps, actuators, valves, etc.), Ophthalmic (preservative-free droppers), Pulmonary (pMDIs, DPIs) and Dermal /Transdermal (airless & atmospheric dispensers). Nemera provides solutions for the pharmaceutical industry, including standard innovative products, the development of proprietary devices and contract manufacturing.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.